OREANDA-NEWS. iX Biopharma Ltd listed on the Catalist board of the Singapore Exchange (SGX) on 22 July, raising S\\$30 million with an IPO market capitalisation of S\\$280 million. Its placement and public offer was 1.4 times, while its public offer was 25 times oversubscribed.

Its listing brings the total number of healthcare companies on SGX to 31, with a combined market capitalisation of over S\\$38 billion.

On its trading debut, iX Biopharma opened at S\\$0.495, 8% above its offer price, and closed 22% higher at S\\$0.560 on the same day.

NauticAWT Ltd listed on Catalist on 23 July, raising S\\$6 million with an IPO market capitalisation of S\\$40 million. Its placement and public offer was six times oversubscribed, while its public offer was 144 times oversubscribed.

NauticAWT’s listing brings the total number of marine and offshore services sector companies to 62, with a market value of more than S\\$50 million.

The stock opened at S\\$0.35, up 75% from its IPO price, and ended 40% higher at S\\$0.280 on the same day.

iX Biopharma

iX Biopharma is a Singapore- incorporated pharmaceutical company focused on the development and commercialisation of products for the treatment of acute pain and erectile dysfunction.  It also provides chemical analysis services for pharmaceutical products. The company manages and undertakes its research and development in Singapore and Australia.

NauticAWT

NauticAWT offers subsurface, subsea and surface facilities engineering and contracting solutions to onshore and offshore segments of the oil and gas industry. The company engages in field exploration, field development, and field refurbishments for its clients. The company operates 11 offices across Southeast Asia, Australia, the Middle East, Latin America, and India. NauticAWT was founded in 2011 and is headquartered in Singapore.